Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial
Primary result · Change in HbA1cResult — go to the resultLS mean difference 0.09 % 95% CI −0.32 to 0.50Authors' conclusion
Over 12 weeks, efsubaglutide alfa 3 mg Q2W provided glycaemic and CGM benefits comparable to 1 mg QW with favourable tolerability. These findings support the feasibility of a biweekly regimen as an alternative to weekly dosing; larger, longer-duration confirmatory trials in more diverse populations are warranted.
Study context
- Population
- Adults with T2D inadequately controlled with lifestyle interventionallocated 1:1
- Participants
- 59 adults
- Comparison
- Efsubaglutide alfa 3 mg biweekly vs 1 mg weekly
- Primary endpoint
- Change in HbA1c from baseline
- Follow-up
- Week 13 (end of 12-week treatment)
Methodological detailsmulticentre, open-label, 1-week 1 mg run-in; 12 weeks treatment
- Multicentre
- Open-label
- 1-week 1 mg run-in; 12 weeks treatment
Primary result
Change in HbA1c · week 13
LS mean difference
0.09 %
95% CI −0.32 to 0.50
Change by group
Q2W
−1.45
SE 0.14 · %
QW
−1.53
SE 0.14 · %
As reported in the abstract
Secondary outcomes
CGM TIR (3.9-10.0 mmol/L)
Tight TIR (3.9-7.8 mmol/L)
HbA1c <7.0% · week 13
HbA1c ≤6.5% · week 13
24-h mean CGM glucose · end of treatment
mmol/L
| Outcome | Q2W | QW |
|---|---|---|
| Change in FPG | −2.07 | −2.22 |
- Continuous glucose monitoring (CGM) time in range (TIR) (3.9-10.0 mmol/L): increased from 45.0%
Change in fasting plasma glucose (FPG)
- FPG fell similarly
Safety
Adverse events
- Hypoglycaemia
- 0
- Cardiovascular events
- 0
- Gastrointestinal AEs predominated, mostly mild to moderate
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →